We have a pipeline of proprietary products in development, including novel sub-unit vaccine candidates directed against both pandemic and seasonal influenza, vaccine candidates for treatment of HPV (human papilloma virus) infections, and vaccine candidates for prevention of anthrax and plague infections. Our platform technology is also being used to develop and produce therapeutic antibodies for treatment of anthrax and influenza.
 
We are evaluating opportunities for partnerships and alliances to ensure clinical development and market penetration of these products. We also offer the benefits of the innovative iBioLaunch™ technology platform to biotechnology and pharmaceutical companies for production of other vaccines, antibodies and therapeutic proteins.